IDEXX Laboratories, Inc. vs Prudential Financial Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Prudential Financial Inc trades at $113.2 (market cap $39.17B). The key difference: IDEXX Laboratories, Inc. and Prudential Financial Inc are close in size by market cap, and Prudential Financial Inc pays a 4.93% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Prudential Financial Inc for 145 Days on average.
| IDXX | PRU | |
|---|---|---|
Market Cap | $40.43B | $39.17B |
Volume | 692,164 | 1,436,917 |
Sector | Health | Financials |
52-Week High | $766.68 | $125.13 |
52-Week Low | $504.70 | $92.00 |
Typical Hold Time | 46 Days | 145 Days |
Enterprise Value | $41.32B | $67.95B |
Dividend Yield | — | 4.93% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Prudential Financial (PRU) trades at $112.97, up 0.54% with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 10.29 and P/S of 0.61, while maintaining solid profitability with 6.04% net margin and 12.46% ROE. Recent strategic moves include the Alexforbes stake sale and rebranding to Prudential Wealth Advisors, reflecting focus on core operations.
While PRU offers value appeal through strong fundamentals and dividend yield, investors face headwinds from bearish technicals and mixed analyst sentiment. The company's capital rotation strategy and PGIM growth initiatives provide upside potential, but execution risks and market volatility remain concerns. Current price sits above consensus target of $105.67, suggesting limited near-term upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →